Welcome to our dedicated page for Kenvue SEC filings (Ticker: KVUE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Kenvue Inc. filings document the public-company disclosures of a pure-play consumer health issuer with brands including Tylenol, Listerine, Johnson’s, Aveeno, Neutrogena and BAND-AID Brand. Its SEC record includes material-event reports, proxy and governance disclosures, shareholder voting matters, capital-structure information, operating and financial results, and consumer-health regulatory topics.
The company’s filings also cover executive officer appointments and compensatory arrangements, material definitive agreements, risk-factor disclosures and common-stock matters. Proxy materials and Form 8-K reports provide formal records of board governance, security-holder votes and other events affecting Kenvue’s corporate structure and reporting obligations.
Kenvue Inc. CFO & CAO Heather Howlett reported an open-market sale of Common Stock. She sold 3,700 shares of Kenvue on June 10, 2026 at a price of $18.105 per share. After this transaction, she directly holds 29,288.37 shares, so the sale represents only a small portion of her reported direct ownership.
The issuer filed a Form 144 notice for proposed sale of Common Stock through Fidelity Brokerage Services LLC on 06/10/2026 with CUSIP 1920008668 on the NYSE. The filing lists 3,700 shares under the securities-to-be-sold section and shows recent restricted stock vesting events totaling 3,700 shares (988, 981, 1,731) on 02/13/2024, 02/13/2025, and 03/05/2025.
Smith Jeffrey C reported acquisition or exercise transactions in this Form 4 filing.
Kenvue Inc. director Jeffrey C. Smith reported his ownership and a new equity award. Investment funds managed by Starboard Value LP hold 27,307,632 shares of Kenvue common stock, which may be attributed to him for reporting purposes, although he disclaims beneficial ownership beyond his pecuniary interest.
Smith also received a grant of 10,309 Deferred Share Units at $17.46 each. These units are to be settled in Kenvue common stock after his board service ends, with each unit delivering one share. Following this grant, he holds 25,432.688 Deferred Share Units directly, including amounts from dividend reinvestment.
Hofstetter Sarah reported acquisition or exercise transactions in this Form 4 filing.
Kenvue Inc. director Sarah Hofstetter received a compensation grant of 10,309 Deferred Share Units (DSUs) on May 21, 2026. Each DSU represents the right to receive one share of Kenvue common stock, generally delivered when her board service ends.
Following this award, Hofstetter holds a total of 24,101.687 DSUs. The grant was valued at $17.46 per unit for reporting purposes and also reflects DSUs credited as dividend equivalents under Kenvue’s Amended and Restated Deferred Fee Plan for Directors.
Kenvue Inc. director Betsy D. Holden received a grant of 10,309 Deferred Share Units at $17.46 per unit under the company’s Amended and Restated Deferred Fee Plan for Directors. Each DSU converts into one share of common stock when her board service ends, bringing her total DSU holdings to 36,626.662 units, including units credited as dividend equivalents. This is a compensation-related equity award rather than an open-market stock purchase or sale.
Kenvue Inc. director Larry J. Merlo received a grant of 16,036 Deferred Share Units (DSUs). The DSUs were awarded at a reference price of $17.46 per unit and are structured to convert into an equal number of Kenvue common shares when his board service ends. After this award, Merlo holds a total of 56,975.45 DSUs, which includes units previously credited as dividend equivalents under the company’s Amended and Restated Deferred Fee Plan for Directors.
PRABHU VASANT M reported acquisition or exercise transactions in this Form 4 filing.
Kenvue Inc. director Vasant M. Prabhu received a grant of 10,309 Deferred Share Units at $17.46 per unit under the company’s Amended and Restated Deferred Fee Plan for Directors. Each DSU represents one share of common stock, settling when his board service ends, bringing his total DSUs to 36,626.664, including amounts from dividend equivalents.
Sneed Michael E reported acquisition or exercise transactions in this Form 4 filing.
Kenvue Inc. director Michael E. Sneed received a grant of 10,309 Deferred Share Units at a reference price of $17.4600 per unit. Each DSU represents the right to receive one share of common stock, to be settled when his directorship ends. Following this award, he holds 36,626.663 DSUs, including units accumulated as dividend equivalents.
Kenvue Inc. Group President LATAM Leonardo Curado Gomes de Lemos reported routine equity compensation activity involving restricted stock units and common stock. He exercised RSUs corresponding to 24,247.71 shares of common stock, with no open-market purchase or sale.
Of the vested shares, 7,141 were withheld to pay taxes, as noted in the footnotes, leaving him with 17,106.71 common shares held directly after the transactions. His derivative holdings now include 48,491.41 restricted stock units, which each correspond 1-for-1 with Kenvue common stock and vest in three equal installments on 05/01/2026, 05/01/2027, and 05/01/2028, subject to continued service.
Kenvue Inc. director Melanie Healey reported a compensation-related grant of 10,309 Deferred Share Units (DSUs) tied to Kenvue common stock at a reference price of $17.46 per unit. Each DSU represents the right to receive one share of common stock, generally settled after her directorship ends.
Following this award, Healey directly holds 36,626.663 DSUs. The filing notes that this balance includes DSUs acquired as dividend equivalents, meaning additional units credited in lieu of cash dividends rather than open-market purchases.